With regard to the mandatory use of mefloquine by Canadian forces personnel, ( a ) what clinical or field studies did the Department of National Defence undertake or fund into the possible adverse effects including the impairment of judgment of the mandatory use of mefloquine by Canadian forces while in Somalia, both while the personnel were in Somalia and on their return to Canada, ( b ) what clinical or field studies did the Department of National Defence undertake or fund into the possible adverse effects including the impairment of judgment of the mandatory use of mefloquine by Canadian forces while in Rwanda, both while the personnel were in Rwanda and on their return to Canada, ( c ) what amount of alcohol was available on a daily basis to Canadian forces personnel in Somalia and later in Rwanda who had received the mandatory dosage of mefloquine, what adjustments or precautions were made to the dosages by those administering the drug and what advice was given to persons required to take mefloquine who might be expected to use alcohol during their tour of duty, ( d ) what screening and other precautions were taken by those administering mefloquine, and what advice was given to Canadian forces personnel in regard to self-administered recreational body building, locally grown stimulants and other such drugs that it could reasonably be expected that personnel might be taking concurrent to their usage of mefloquine, ( e ) what ranks and occupations in the Canadian forces were not subject to the mandatory use of mefloquine in either Somalia or Rwanda and why were they not subject to the mandatory requirement to take mefloquine and ( f ) why is the effective dosage of mefloquine taken by Canadian forces stronger than the equivalent dosage given U.S. military personnel and what are the possible adverse effects of such stronger dosages?
In the House of Commons on April 3rd, 1995. See this statement in context.